Charles W. Newton - Mar 17, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Financial Officer
Signature: /s/ Matthew Lang, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Mar 17, 2025
Transactions value $: $111,620
Form type: 4
Date filed: 3/18/2025, 07:01 PM
Previous filing: Feb 26, 2025
Next filing: Apr 29, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Purchase	$112K	+200K		$0.56	200K	Mar 17, 2025	Co-grantor and Co-trustee	F1, F2
holding	LYEL	Common Stock						173K	Mar 17, 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.54 to $0.56, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range
F2	Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.

Content

The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.54 to $0.56, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range

Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.